Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update

ATLANTA, November 13, 2026 — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended September 30, 2026 and provides a corporate update.

Corporate Highlights from 3Q 2026 to date

•

Completed $30 million private placement with potential total proceeds of up to $85 million upon full cash exercise of warrants, to build-out the U.S. commercial team needed to support revenue growth following recent availability of the FemaSeed® fertility portfolio to OB/GYNs, and to fund the FemBloc® pivotal trial to support U.S. approval.

•

Highlights for the FemaSeed Fertility Portfolio (Diagnostics: FemVue® for her and SpermVueTM for him; first-step treatment: FemaSeed and FemSperm®):

o

Announced a partnership with both UNC Health and Minnesota Women’s Care to introduce the entire portfolio across its OB/GYN practice locations.

o

Announced a partnership with CapexMD to expand patient access through financing solutions and SandsRx Pharmacy for medications to support treatment timing.

•

Highlights for FemBloc Permanent Birth Control:

o

Issuance of patents in the U.S. and key international markets that expand intellectual property protection for the blended polymer component.

o

Received FDA approval of the modular premarket approval (PMA) submission approach.

o

Announced the number of actively enrolling sites in the FINALE trial to support U.S. approval doubled to twelve sites.

“We maintained a lean team and tightly managed resources as we prioritized financing from long-term institutional investors. Closing the $30 million in financing in mid-August 2026 represents an important turning point for Femasys,” said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. “With U.S. fertility rates at historic lows, there is an urgent need to bring treatment to the OB/GYN office, where women already seek care. Our portfolio enables these physicians to offer a complete pathway from diagnostics through first-step treatment, supported by partnerships that simplify access to patient financing and fertility medications. Since closing the financing, we have been successfully recruiting commercial professionals with deep OB/GYN expertise and established relationships. Healthcare system partnerships and initial sales achieved with limited resources demonstrate the commercial potential of our comprehensive fertility portfolio. These results and commercial recruitment progress give us strong confidence that deploying our team in target U.S. territories will broaden adoption and drive revenue growth.”

Financial Results for Quarter Ended September 30, 2026

•

Sales in the U.S. increased slightly to $347,039 in 2026 from $336,594 in 2025, while overall sales decreased by $324,797, or 44.5%, to $404,597 from $729,394. The overall decline was anticipated and reflects the timing of international FemBloc orders, consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed.

•

Research and development expenses increased by $560,905, or 40.6%, to $1,942,927 in 2026 compared to $1,382,022 in 2025, primarily reflecting the transition of development products into inventory to support commercialization during 2025, and increased clinical costs and compensation costs during 2026.

•

Net loss was $4,564,815, or ($0.53) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2026, compared to a net loss of $4,194,821, or ($2.05) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2025.

Financial Results for Nine Months Ended September 30, 2026

•

Sales in the U.S. increased slightly to $1,038,997 in 2026 from $1,015,168 in 2025, while overall sales decreased by $318,613, or 21.5%, to $1,161,313 from $1,479,926. The overall decline was anticipated and reflects the timing of international FemBloc orders, consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed.

•

Research and development expenses decreased by $565,717, or 9.8%, to $5,199,206 in 2026 compared to $5,764,923 in 2025, primarily reflecting lower compensation costs, regulatory fees and outside consultant costs, partially offset by increased clinical costs and material and development costs.

•

Net loss was $8,187,810, or ($1.59) per basic and diluted share attributable to common stockholders, for the nine months ended September 30, 2026, compared to a net loss of $14,677,582, or ($9.25) per basic and diluted share attributable to common stockholders, for the nine months ended September 30, 2025.

•

Cash and cash equivalents as of September 30, 2026, were approximately $23.9 million and the Company had an accumulated deficit of approximately $154.0 million.

For more information, please refer to the Company’s Form 10-Q filed November 13, 2026, which can be accessed on the SEC website.

FEMASYS INC.

Condensed Balance Sheets

(unaudited)

Assets		September 30, 2026				December 31, 2025
Current assets:
Cash and cash equivalents		$	23,913,946				9,266,353
Accounts receivable, net			233,778				616,600
Inventory			6,166,371				5,740,249
Prepaid and other current assets			893,098				833,133
Total current assets			31,207,193				16,456,335
Property and equipment, at cost:
Leasehold improvements			1,238,886				1,238,886
Office equipment			91,610				78,155
Furniture and fixtures			424,586				417,876
Machinery and equipment			3,125,855				3,065,713
Construction in progress			991,124				897,885
			5,872,061				5,698,515
Less accumulated depreciation			(3,991,222	)			(3,802,940	)
Net property and equipment			1,880,839				1,895,575
Long-term assets:
Lease right-of-use assets, net			952,796				1,297,121
Intangible assets, net of accumulated amortization			99,902				134,914
Other long-term assets			946,928				940,232
Total long-term assets			1,999,626				2,372,267
Total assets		$	35,087,658				20,724,177

(continued)

FEMASYS INC.

Condensed Balance Sheets

(unaudited)

Liabilities and Stockholders’ Equity		September 30, 2026				December 31, 2025
Current liabilities:
Accounts payable		$	$1,958,546				1,830,124
Accrued expenses			855,377				1,265,773
Note payable			292,229				—
Clinical holdback – current portion			29,250				52,644
Operating lease liabilities – current portion			465,960				487,624
Total current liabilities			3,601,362				3,636,165
Long-term liabilities:
Clinical holdback – long-term portion			58,179				52,370
Convertible notes payable, net			3,717,653				3,178,864
Conversion option liability			—				2,014,000
Warrants liabilities			—				4,943,000
Operating lease liabilities – long-term portion			682,302				1,030,476
Total long-term liabilities			4,458,134				11,218,710
Total liabilities			8,059,496				14,854,875
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par, 200,000,000 shares authorized, 8,662,139 shares issued and 8,656,277 shares outstanding as of  September 30, 2026; and 2,986,116 shares issued  and 2,980,254 shares outstanding as of December 31, 2025
			8,662				2,986
Treasury stock, 5,862 common shares			(60,000	)			(60,000	)
Warrants			19,023,695				5,246,150
Additional paid-in capital			162,069,759				146,506,310
Accumulated deficit			(154,013,954	)			(145,826,144	)
Total stockholders’ equity			27,028,162				5,869,302
Total liabilities and stockholders' equity		$	35,087,658				20,724,177

FEMASYS INC.

Condensed Statements of Operations

(unaudited)

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Sales		$	404,597				729,394				1,161,313				1,479,926
Cost of sales (excluding depreciation expense)			187,496				293,838				488,538				569,275
Operating expenses:
Research and development			1,942,927				1,382,022				5,199,206				5,764,923
Sales and marketing			943,002				1,143,805				3,552,755				3,037,349
General and administrative			1,704,091				1,477,800				5,418,059				4,817,485
Depreciation and amortization			77,091				85,697				242,172				256,835
Total operating expenses			4,667,111				4,089,324				14,412,192				13,876,592
Loss from operations			(4,450,010	)			(3,653,768	)			(13,739,417	)			(12,965,941	)
Other income (expense):
Interest income			85,610				17,315				155,131				53,488
Change in fair value of Conversion Option liability			—				—				1,732,413				—
Change in fair value of Warrants liabilities			—				—				4,228,000				—
Interest expense			(200,415	)			(532,073	)			(563,072	)			(1,483,022	)
Other expense			—				(26,295	)			—				(286,295	)
Total other income (expense), net			(114,805	)			(541,053	)			5,552,472				(1,715,829	)
Loss before income taxes			(4,564,815	)			(4,194,821	)			(8,186,945	)			(14,681,770	)
Income tax expense (benefit)			—				—				865				(4,188	)
Net loss		$	(4,564,815	)			(4,194,821	)			(8,187,810	)			(14,677,582	)
Net loss attributable to common stockholders		$	(4,564,815	)			(4,194,821	)			(8,187,810	)			(14,677,582	)
Basic and diluted loss per share		$	(0.53	)			(2.05	)			(1.59	)			(9.25	)
Weighted-average common shares and pre-funded warrants outstanding, basic and diluted			8,660,381				2,050,761				5,136,109				1,586,992

Forward-Looking Statements

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

# # #

Contacts:

[email protected]

[email protected]